Graphene oxide immobilized 2-morpholinoethanamine as a versatile acid-base catalyst for synthesis of some heterocyclic compounds and molecular docking study.

Autor: Amiri-Zirtol L; Department of Chemistry, Yazd University, Yazd, Iran. l.amiri@rocketmail.com., Ahooie TS; Chemistry and Chemical Engineering Research Center of Iran, Tehran, Iran., Riazimontazer E; Biotechnology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran., Amrollahi MA; Department of Chemistry, Yazd University, Yazd, Iran., Mirjalili BF; Department of Chemistry, Yazd University, Yazd, Iran.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2023 Oct 20; Vol. 13 (1), pp. 17966. Date of Electronic Publication: 2023 Oct 20.
DOI: 10.1038/s41598-023-44521-9
Abstrakt: In this study, a new heterogeneous catalyst was synthesized based on graphene oxide (GO) as a natural material. On the surface of nanosheet graphene oxide, 2-Morpholinoethanamine was immobilized using a non-toxic, green, and simple method. This resulted in the preparation of a bifunctional acid-base nanocatalyst. The synthesized composite was fully characterized using various methods, including Fourier transform infrared spectrometry (FT-IR), scanning electron microscopy (FESEM), energy dispersive X-ray spectroscopy (EDS), mapping, Raman spectroscopy, X-ray diffractometry (XRD), thermogravimetric analysis (TGA), and CHN elemental analysis. The catalytic reactivity of GO-mor was investigated in the one-pot synthesis of some benzo[b]pyran, pyrano[3,2-c]chromene, and polyhydroquinoline derivatives, yielding good efficiency and short reaction times. In addition, several recent studies have shown that some derivatives of pyran, chromene, and quinoline have remarkable anti COVID activity. Particularly, COVID-19 3CLpro/Mpro is considered a potential target for the treatment of this virus. For this purpose, docking models were constructed using the corresponding crystal structures with the synthesized derivatives. Based on the docking score and similarity of the binding mode to remdesivir and elvitegravir (the only approved drugs for the treatment of COVID-19), A 2 , B 1 , and C 4 were selected as promising candidates for further research.
(© 2023. Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje